PetVivo Holdings, Inc. (NASDAQ: PETV), is new to the NASDAQ and has historically been a light trader in terms of volume. September however marked a record month, trading close to 30 million shares or $100 million in dollar volume.
There are major benefits to up listing to a senior exchange. One benefit is the possibility that analysts are beginning to cover the stock. A covered stock refers to a public company’s shares for which one or more sell-side equity analysts publish research reports and investment recommendations for their clients.
The beginning of October marked a 30% increase in the stock as Think Equity has initiated coverage on the stock with a $7.00 price target.
To view the Think Equity report Click here.
PetVivo Holdings, Inc. (NASDAQ: PETV) is a company that checks all the boxes:
- Uplisted to NASDAQ from the OTCQB
- Total addressable market $4.8 billion with 5% annual growth
- Has a product that treats the affliction, not just the symptoms
- Miminum FDA Risk
- Scalable manufacturing
- Seasoned Staff
- Acquisiton & sales minded
- Patent Protection
Think Equity in Summary stated the following:
“The company received net proceeds of $9.8 million from the capital raise in August. We expect the company to step up marketing to support the product rollout. At the forecast cash burn, the current cash position of $8.5 million should support operations through third calendar quarter of 2022.
We forecast revenues to grow from $0.3 million in FY 2022 to $12.0 million by FY 2024. We are modeling gross margins to expand from 11% to 65% over the same period. We expect EBITDA to improve from $(3.7) million in fiscal 2022 to $(2.4) million in 2024.”
The global veterinary surgical instruments market is estimated to reach USD 1,029.0 million by 2021 from USD 748.4 million in 2016, grow at a CAGR of 6.6% during the forecast period as reported by Research and Markets.
The companion animal osteoarthritis market in the United States is estimated at $4.4 billion, growing at about 7% annually. The market size only represents dogs and horses, as the company’s treatment currently is for dogs and horses. The company expects a feline product within six months that expands the available market.
PetVivo Holdings, Inc. (NASDAQ: PETV) is a company you need to look at if you want to capitalize on growth in the space.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals.
The Company just announced that Joe Manning, DVM has been engaged to work with the Company as a Senior Technical Veterinarian. Dr. Manning has more than 30 years of veterinary experience in the Animal Health Industry holding various roles as a practicing veterinarian, as well as a key contributor in product development and commercialization of therapeutic veterinary products.
PetVivo, Inc. (NASDAQ: PETV), is the producer of “Spryng”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses that is intended to provide a lubricious cushion within the joint and between the bones to reinforce cartilage. Spryng is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Spryng is made from natural materials (collagen elastin and heparin), typically lasts for 12 months or longer and can be repeated annually or as needed.
PetVivo is expected to expand commercial production and availability of Spryng in Q1 2021, in the $4.8 billion dog and horse therapeutics market.
Motley Fool recently discussed two veterinary companies. They named Trupanion (NASDAQ: TRUP) as a stock that could turn a $25,000.00 investment into $1 million or more, and it also recently reported that Idexx Laboratories (NASDAQ: IDXX), is up almost 34% year to date and at an all-time high after the acquisition of ezyVet in June.
The sector is hot and PetVivo Holdings (NASDAQ: PETV) could just be that horse waiting get out of the gate.
Petvivo (NASDAQ: PETV) recently announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to the Company’s proprietary encapsulated or coated stent systems. The company currently has 16 products in its pipeline, and a portfolio of 19 patents that protect them.
PetVivo Holdings, Inc. made a name for itself when a successful Spryng case study came to light when Fender Bender, a racehorse suffering from osteoarthritis, was put up for sale and claimed for $3,000.00 and the new owner treated him with PetVivo’s Spryng. Fender Bender won at Canterbury Park on August 4, 2020.
https://www.youtube.com/watch?v=W5NRY2k9uIM&feature=youtu.be
Any of the majors in the space could benefit from PetVivo’s proprietary assets, but while PetVivo may or may not be on a “seeking to be acquired” path, it is on an aggressive growth / valuation path.
In June of 2018, Dr. Turner was added to PetVivo’s advisory board.
In the presentation, Dr. Turner recalls a horse with an injured meniscus that was no longer responsive to any other therapy. As a last resort, he injected the horse with Spryng, and at his follow up appointment two weeks later, Dr. Turner was so amazed at the results that he thought the owner switched horses on him.
Advances in veterinary health care are providing meaningful improvement in our pets’ lives. There are ongoing innovations in veterinary treatments, preventative medications, diagnostics, screening tools, imaging (MRIs and other scans), wellness products and therapies supported by owners willing to pay for these treatments.
As an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals, PetVivo Holdings, Inc. is leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
On August 10, 2021, The common shares and warrants have been approved to list on the Nasdaq Capital Market under the symbols “PETV” and “PETVW” respectively, and are expected to begin trading on Wednesday, August 11, 2021.
If you are looking for value in the space in the form of a company with proprietary technology that could either realize exponential growth, or be acquired by a major who would rather buy the wheel then reinvent it, look no further than PetVivo Holdings, Inc. (NASDAQ: PETV).
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in an effective and time efficient manner.
The audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All Conferences are first announced on Twitter – Follow us on Twitter
All Conference replays emerge on our YouTube Channel – Subscribe to our YouTube Channel
If you believe your company, product or service is at the cusp of going mainstream, or you have an idea for an “Emerging Growth” company that might fit our model, contact us here.
This is an advertisement and not an offer or solicitation to buy or sell any securities. All information and material contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable and / or provided to EmergingGrowth.comby a third party, but not guaranteed to be accurate or all-inclusive. All material contained within this article, is for informational purposes only, is not the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated thirteen thousand one hundred dollars in consideration for its work with PetVivo Holdings, Inc. for distribution of this content. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here, https://emerginggrowth.com/68372-7388/. You can easily lose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.
